LAVAL, Quebec, Aug. 8, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced its commitment to improving the lives of Wilson disease patients around the world.
Valeant has agreed to provide $100,000 to fund enhanced patient awareness and research into this debilitating disease. This charitable contribution will be used to further the ongoing mission of the Wilson Disease Association (WDA) to facilitate and promote the identification, education, treatment and support of patients and other individuals affected by the disease. In addition to this contribution, Valeant has committed to augmenting its patient services hub for Wilson disease to improve both the patient and prescriber experience under the Valeant Coverage Plus Program. Valeant also plans to collaborate with the WDA to develop an educational app for iPhone and iPad to serve as a resource platform for patients.
"We are very pleased to support the Wilson Disease Association, an important organization that is dedicated to a critical therapeutic area," said Joseph C. Papa, chairman and chief executive officer of Valeant. "This collaboration underscores our focus on improving the lives of patients around the world, especially those affected by Wilson disease."
"We greatly appreciate the contributions that Valeant is making to Wilson disease patients," said Mary L. Graper, president of the Wilson Disease Association. "Enhancing awareness and promoting education around this disease is critical, and we believe that Valeant's efforts will allow us to do more to ensure the well-being of patients and their families."
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
This press release may contain forward-looking statements, including, but not limited to, statements regarding the collaboration with the Wilson Disease Association. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-significant-support-for-education-and-research-regarding-wilson-disease-300310703.html
SOURCE Valeant Pharmaceuticals International, Inc.